Price ‘Anchoring’? Zolgensma And The Art Of Managing Gene Therapy Sticker Shock
Executive Summary
Public statements by Novartis and AveXis suggest Zolgensma could be cost effective at a price up to $5m. Analysts expect $2m. The lower estimate is still stunning, but could it be considered reasonable by comparison?
You may also be interested in...
ICER Will Explore Value Pricing For Cures In Context Of ‘Shared’ Health System Savings
Future value assessments will include ‘hypothetical’ scenarios in which downstream medical savings will be shared between the health care system and the treatment developer.
ICER Value Framework Update Reaffirms Support For Real-World Evidence
Drug makers have sought a larger role for RWE in ICER's review process; proposed update also includes process to re-evaluate cost-effectiveness evidence after one year.
New Payment Models For Curative Treatments Have CMS’ Attention, Verma Says
US Centers for Medicare and Medicaid Services administrator Seema Verma discusses solutions for handling the high cost of gene therapy and the Trump administration’s drug pricing agenda in briefing with reporters.